Pulmatrix Stock Current Valuation
| PULM Stock | USD 6.29 0.25 4.14% |
Valuation analysis of Pulmatrix helps investors to measure Pulmatrix's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Pulmatrix's Enterprise Value Over EBITDA is very stable compared to the past year. As of the 27th of November 2024, Enterprise Value Multiple is likely to grow to 0.29, while Enterprise Value is likely to drop (3.8 M). Fundamental drivers impacting Pulmatrix's valuation include:
Price Book 2.0201 | Enterprise Value 11.3 M | Enterprise Value Ebitda 1.5719 | Price Sales 1.9364 | Enterprise Value Revenue 1.1272 |
Undervalued
Today
Please note that Pulmatrix's price fluctuation is very risky at this time. Calculation of the real value of Pulmatrix is based on 3 months time horizon. Increasing Pulmatrix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pulmatrix stock is determined by what a typical buyer is willing to pay for full or partial control of Pulmatrix. Since Pulmatrix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pulmatrix Stock. However, Pulmatrix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.29 | Real 7.4 | Target 10.0 | Hype 8.27 |
The intrinsic value of Pulmatrix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pulmatrix's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pulmatrix helps investors to forecast how Pulmatrix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pulmatrix more accurately as focusing exclusively on Pulmatrix's fundamentals will not take into account other important factors: Pulmatrix Company Current Valuation Analysis
Pulmatrix's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pulmatrix Current Valuation | 11.28 M |
Most of Pulmatrix's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pulmatrix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pulmatrix Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Pulmatrix is extremely important. It helps to project a fair market value of Pulmatrix Stock properly, considering its historical fundamentals such as Current Valuation. Since Pulmatrix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pulmatrix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pulmatrix's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pulmatrix has a Current Valuation of 11.28 M. This is 99.92% lower than that of the Pharmaceuticals sector and 99.76% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.93% higher than that of the company.
Pulmatrix Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pulmatrix's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pulmatrix could also be used in its relative valuation, which is a method of valuing Pulmatrix by comparing valuation metrics of similar companies.Pulmatrix is currently under evaluation in current valuation category among its peers.
Pulmatrix ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pulmatrix's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pulmatrix's managers, analysts, and investors.Environmental | Governance | Social |
Pulmatrix Fundamentals
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (0.95) % | ||||
| Operating Margin | (3.80) % | ||||
| Current Valuation | 11.28 M | ||||
| Shares Outstanding | 3.65 M | ||||
| Shares Owned By Institutions | 7.16 % | ||||
| Number Of Shares Shorted | 7.05 K | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 2.02 X | ||||
| Price To Sales | 1.94 X | ||||
| Revenue | 7.3 M | ||||
| Gross Profit | 6.07 M | ||||
| EBITDA | (13.27 M) | ||||
| Net Income | (14.12 M) | ||||
| Cash And Equivalents | 42.91 M | ||||
| Cash Per Share | 12.67 X | ||||
| Total Debt | 8.76 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.19 X | ||||
| Book Value Per Share | 4.93 X | ||||
| Cash Flow From Operations | (15.98 M) | ||||
| Short Ratio | 0.75 X | ||||
| Earnings Per Share | (2.64) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 22 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 22.06 M | ||||
| Total Asset | 33.96 M | ||||
| Retained Earnings | (287.6 M) | ||||
| Working Capital | 16.93 M | ||||
| Current Asset | 8.34 M | ||||
| Current Liabilities | 4.11 M | ||||
| Net Asset | 33.96 M |
About Pulmatrix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pulmatrix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pulmatrix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pulmatrix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Pulmatrix Piotroski F Score and Pulmatrix Altman Z Score analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 3.119 | Quarterly Revenue Growth (0.16) | Return On Assets (0.30) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.